Lever
Lifestyle
- Regular aerobic exercise
- Weight management
- Smoking cessation
Blutwerte · Marker
Non-HDL-Cholesterin
Non-HDL Cholesterol · Non-HDL-C
Lipide & Herz-Kreislauf
- Einheit:
- mmol/L
- Abbreviation
- Non-HDL-C
Non-HDL-C quantifies the total cholesterol content in all atherogenic lipoproteins, excluding HDL.
Reference Ranges
Reference
0–3.9mmol/L
0
3.5
3.9
LowNormalHigh
Reference
Optimal
Unit · mmol/LNon-fasting samples are acceptable; values above 3.9 mmol/L are flagged as abnormal.
Overview
Übersicht
Non-HDL-Cholesterol (Non-HDL-C) is a lipid biomarker that measures the total cholesterol content in all atherogenic lipoproteins, excluding high-density lipoprotein (HDL). It is calculated by subtracting HDL cholesterol from total cholesterol. Non-HDL-C is considered a comprehensive marker for assessing cardiovascular risk because it encompasses all lipoprotein particles that contribute to plaque formation in arteries. Clinically, elevated non-HDL-C levels are associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease and stroke. It is particularly useful in evaluating individuals with hypertriglyceridemia, where traditional LDL-C measurements may be less reliable. For athletes and biohackers, maintaining optimal non-HDL-C levels is crucial for cardiovascular health and longevity. Elevated levels could indicate an imbalance in lipid metabolism, potentially affecting performance and recovery. Researchers found that non-HDL-C levels can be assessed without fasting, making it a convenient marker for routine health checks. However, factors such as recent dietary intake, acute illness, and genetic predispositions can influence non-HDL-C levels. It is important to consider these variables when interpreting results, and repeated testing may be necessary to confirm abnormal values.
Klinische Bedeutung
Elevated non-HDL-C levels indicate a higher risk of atherosclerotic cardiovascular disease. Reduced levels are generally considered favorable and reflect a lower cardiovascular risk.
Dynamics
Trend Interpretation
Rising Values
Progressively rising non-HDL-C values suggest worsening lipid profile and increased cardiovascular risk. Re-test in 4-6 weeks if values are outside the optimal range.
Falling Values
Progressively falling values indicate improvement in lipid management and reduced cardiovascular risk.
Re-test Interval
4-6 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Diet high in saturated fats
- Familial hypercholesterolemia
- Obesity
- Diabetes mellitus
- Hypothyroidism
- Chronic kidney disease
Cause
Low Levels
- Hyperthyroidism
- Malabsorption syndromes
- Chronic liver disease
- Malnutrition
- Certain medications (e.g., statins)
- Acute illness
Protocol
How to Optimize
Lever
Nutrition
- Increase intake of omega-3 fatty acids
- Consume more soluble fiber
- Limit intake of trans fats
Lever
Supplementation
- Fish oil
- Plant sterols
Note:
Consult a healthcare provider before starting any supplementation, especially if on medication.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Annually for healthy adults, more frequently if at risk for cardiovascular disease
Interfering Factors
- Recent dietary intake
- Acute illness
- Genetic factors
Related Peptides & Hormones
Apolipoprotein B
hormone or peptideCorrelated with
Open Research Questions
Current research suggests that reference ranges and optimal targets for non-HDL cholesterol (non-HDL-C) and the non-HDL-C/HDL-C ratio (NHHR) remain debated, particularly in diverse populations and specific conditions like sarcopenia and sepsis. Researchers have not yet established standardized thresholds for NHHR across different demographics. Unanswered clinical questions include the precise mechanisms linking NHHR to sarcopenia and sepsis mortality, as well as the potential role of lifestyle modifications in managing these risks.
24 Research Publications
1,186
Total Citations
10
Human/RCT
5.0
Avg. Influence
2025
Latest
Sort
Filter
01Top
#01
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.
Nordestgaard Børge G, et al. · European heart journal · 2016
ReviewInfluence33.0
819
Researchers found that non-fasting lipid profiles can be used routinely without significant clinical differences compared to fasting profiles. They recommend flagging abnormal non-HDL cholesterol levels at 3.9 mmol/L (150 mg/dL) and suggest that both fasting and non-fasting measurements can complement each other in assessing cardiovascular risk.
Key findings
- 01Researchers observed that changes in lipid levels after eating are minimal and not clinically significant.
- 02They found that non-fasting and fasting lipid profiles can predict cardiovascular disease risk similarly.
- 03The study suggests flagging abnormal lipid levels in lab reports to help identify potential health issues.
02Top
#02
Ezetimibe: cholesterol lowering and beyond.
ReviewInfluence4.0
150
This study evaluated the cholesterol-lowering effects of ezetimibe and its broader impacts on cardiovascular risk. Researchers found that ezetimibe not only lowers LDL cholesterol but also positively affects other lipid parameters, including non-HDL cholesterol. They noted ongoing studies to assess its clinical significance.
03Top
#03
LOX-1 in atherosclerotic disease.
HumanInfluence1.0
49
This study investigated the role of LOX-1 in atherosclerotic disease. Researchers found that levels of LOX-1 ligands were positively associated with carotid intima-media thickness and cardiovascular events, independent of LDL cholesterol levels. They suggested that LOX-1 could serve as a valuable biomarker for assessing atherosclerosis risk.
04
#04
Update on the laboratory investigation of dyslipidemias.
Review
40
Researchers reviewed the evolving role of clinical laboratories in assessing cardiovascular disease risk through lipid measurements. They highlighted non-HDL-C as a valuable alternative for evaluating lipid profiles and emphasized the need for standardization in testing methods.
05
#05
Hypertriglyceridemia in Obese Children and Adolescents.
HumanInfluence2.0
34
This study addressed hypertriglyceridemia in obese children and adolescents, linking elevated triglyceride levels to cardiometabolic risk. Researchers recommended universal lipid screening, including non-HDL-C measurements, to identify at-risk youth.
06
#06
Biomarker variability and cardiovascular disease residual risk.
ReviewInfluence3.0
20
Researchers reviewed the impact of biomarker variability on cardiovascular disease risk, noting that fluctuations in lipid levels can contribute to residual risk. They emphasized the need for standardized approaches to assess this variability effectively.
07
#07
The clinical and laboratory investigation of dysbetalipoproteinemia.
ReviewInfluence3.0
15
Researchers highlighted that familial dysbetalipoproteinemia is often underdiagnosed and associated with increased cardiovascular risk. They noted that standard lipid profiles may not distinguish this condition, suggesting the use of apolipoprotein B as a more effective initial diagnostic test.
08
#08
Non-High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History.
Review
12
Researchers reviewed the evolution of cholesterol treatment guidelines over the years, focusing on the significance of non-HDL cholesterol as a target for treatment. The article emphasizes the advantages of non-HDL cholesterol over LDL cholesterol in assessing cardiovascular risk and recommends its inclusion in laboratory reports.
09
#09
Lipoprotein Assessment in the twenty-first Century.
ReviewInfluence1.0
11
Researchers provided an update on the relationship between lipoprotein levels and cardiovascular disease, emphasizing the importance of accurate lipid assessment in clinical practice. They noted that recent advances in testing can improve cardiovascular risk evaluation.
10
#10
Laboratory evaluation of lipid parameters in clinical practice.
ReviewInfluence1.0
11
Researchers highlighted the importance of accurate lipid measurements for coronary artery disease prevention. They noted that standardized testing methods are essential for effective risk estimation and treatment initiation in clinical settings.
Publication Trend
Research publications about Non-HDL-Cholesterin over time
10totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer